MIM
EVLO

MetLife Investment Management’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

MetLife Investment Management’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-608
Closed -$167K – 2588
2021
Q2 		$167K Buy
+608
New +$153K ﹤0.01% 2263

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MetLife Investment Management's EVLO Position: Q3 2021 in Review

MetLife Investment Management sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q3 2021, closing a stake of 608 shares — an estimated $167K sold.

MetLife Investment Management first reported a position in EVLO in Q2 2021 and held it in 1 quarter. The position peaked at $167K in Q2 2021. 64 funds tracked by Wall St. Rank hold EVLO as of Q3 2021.

  • MetLife Investment Management reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • MetLife Investment Management sold 608 Evelo Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $167K.
  • MetLife Investment Management first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • MetLife Investment Management's Evelo Biosciences, Inc. Common Stock position peaked at $167K in Q2 2021.
  • 64 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q3 2021.

Based on MetLife Investment Management's 13F filing for Q3 2021, filed 15 Nov 2021.